Cargando…

Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma

In this study, Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), Choi and modified Choi criteria were compared to determine which method is optimal for response evaluation in hepatocellular carcinoma (HCC) patients treated with transarterial radioembolization (TARE) w...

Descripción completa

Detalles Bibliográficos
Autores principales:	WENG, ZHIHONG, ERTLE, JUDITH, ZHENG, SHAOPING, LAUENSTEIN, THOMAS, MUELLER, STEFAN, BOCKISCH, ANDREAS, GERKEN, GUIDO, YANG, DONGLIANG, SCHLAAK, JOERG F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834326/ https://www.ncbi.nlm.nih.gov/pubmed/24260066 http://dx.doi.org/10.3892/ol.2013.1612

Ejemplares similares

A New Model to Estimate Prognosis in Patients with Hepatocellular Carcinoma after Yttrium-90 Radioembolization
por: Weng, Zhihong, et al.
Publicado: (2013)

Selective internal radiation therapy of hepatic tumors: procedural implications of a patent hepatic falciform artery
por: Schelhorn, Juliane, et al.
Publicado: (2014)

Transarterial radioembolization for hepatocellular carcinoma: a review
por: Sacco, Rodolfo, et al.
Publicado: (2016)

Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Vardar, Baran U, et al.
Publicado: (2022)

Radioembolization with Y-90 Glass Microspheres: Do We Really Need SPECT-CT to Identify Extrahepatic Shunts?
por: Theysohn, Jens M., et al.
Publicado: (2015)

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
por: Kallini, Joseph Ralph, et al.
Publicado: (2016)

Combining Immunotherapy with Transarterial Radioembolization
por: Balaban Genc, Zeynep Ceren, et al.
Publicado: (2023)

Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy
por: Feng, Rui, et al.
Publicado: (2023)

Transarterial Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma Invading the Right Atrium
por: Girardet, Raphaël, et al.
Publicado: (2020)

Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report
por: Ljuboja, Damir, et al.
Publicado: (2020)

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma
por: Chan, Hui-Wen, et al.
Publicado: (2022)

Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?
por: Benkö, Tamás, et al.
Publicado: (2022)

Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement
por: Şener, Nur, et al.
Publicado: (2023)

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis
por: Hur, Moon Haeng, et al.
Publicado: (2023)

Short-term changes of angiogenesis factors after transarterial radioembolization in hepatocellular carcinoma patients
por: Ballı, Hüseyin Tuğsan, et al.
Publicado: (2023)

Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients
por: Chung, Sung Won, et al.
Publicado: (2023)

Retrospective SPECT/CT dosimetry following transarterial radioembolization
por: Thompson, Briana C., et al.
Publicado: (2021)

Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Yang, Yi, et al.
Publicado: (2018)

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients
por: Teyateeti, Ajalaya, et al.
Publicado: (2020)

Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients
por: Yim, Sun Young, et al.
Publicado: (2022)

Selecting the Right Tool for the Right Job: Which Response Criteria Better Predicts Survival of Patients Treated with Transarterial Radioembolization?
por: Kim, Bo Hyun
Publicado: (2020)

Transarterial Radioembolization (TARE) Agents beyond (90)Y-Microspheres
por: Bouvry, C., et al.
Publicado: (2018)

Transarterial radioembolization with Yttrium-90: current status and future prospects
por: Yang, Hua-Yu, et al.
Publicado: (2020)

Novel (175)Yb-Poly (L-Lactic Acid) Microspheres for Transarterial Radioembolization of Unrespectable Hepatocellular Carcinoma
por: Jamre, Mina, et al.
Publicado: (2019)

A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study
por: Lam, Marnix, et al.
Publicado: (2022)

Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy
por: Goh, Myung Ji, et al.
Publicado: (2020)

Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria
por: d’Abadie, Philippe, et al.
Publicado: (2022)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
por: Lee, Jae Seung, et al.
Publicado: (2020)

Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports
por: Carvalho, Vithor de Oliveira, et al.
Publicado: (2020)

Diagnostic Performance of Theranostic Radionuclides Used in Transarterial Radioembolization for Liver Cancer
por: Li, Rou, et al.
Publicado: (2021)

Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments
por: Cappelli, Alberta, et al.
Publicado: (2014)

Sarcopenia Worsening One Month after Transarterial Radioembolization Predicts Progressive Disease in Patients with Advanced Hepatocellular Carcinoma
por: Vallati, Giulio Eugenio, et al.
Publicado: (2021)

LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma
por: Yoon, Jongjin, et al.
Publicado: (2021)

Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma
por: Reincke, Marlene, et al.
Publicado: (2022)

Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study
por: Kolligs, Frank, et al.
Publicado: (2022)

Non-Invasive Imaging Biomarkers to Predict the Hepatopulmonary Shunt Fraction Before Transarterial Radioembolization in Patients with Hepatocellular Carcinoma
por: Hamm, Charlie Alexander, et al.
Publicado: (2023)

Imaging evaluation following transarterial radioembolization with yttrium-90 microspheres downstaging hepatocellular carcinoma: the first case in China
por: Li, Xiaoming, et al.
Publicado: (2023)

Selecting the Appropriate Downstaging and Bridging Therapies for Hepatocellular Carcinoma: What Is the Role of Transarterial Radioembolization? A Pooled Analysis
por: Lopez-Lopez, Victor, et al.
Publicado: (2023)

Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial
por: Seinstra, Beatrijs A, et al.
Publicado: (2012)

Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma
por: Mohamed, Mostafa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vp6ngi21bogo9i327k5rvqjtfg